更新于：2024-11-01

Bacampicillin Hydrochloride

盐酸巴氨西林

更新于：2024-11-01

概要

概要

基本信息

药物类型

小分子化药

别名

1'-ethoxycarbonyloxyethyl-(6-D-α-aminophenylacetamido)penicillanate、1-[(ethoxycarbonyl)oxy]ethyl (2S,5R,6R)-6-{[(2R)-2-amino-2-phenylacetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate、Bacampicillin

+ [4]

靶点

PBPs

作用机制

PBPs抑制剂(细菌青霉素结合蛋白家族抑制剂)

治疗领域

感染消化系统疾病眼部疾病+ [7]

在研适应症

急性支气管炎附件炎烧伤+ [25]

非在研适应症-

原研机构

Pfizer Inc.

在研机构

Nichi-Iko Pharmaceutical Co., Ltd.

黑龙江福和制药集团股份有限公司Astra Lakemedel AB

非在研机构

Pfizer Laboratories (Pty) Ltd.

最高研发阶段批准上市

首次获批日期

美国 (1980-12-22),

淋病呼吸道感染泌尿道感染

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构

分子式C21H27N3O7S

InChIKeyPFOLLRNADZZWEX-FFGRCDKISA-N

CAS号50972-17-3

查看全部结构式(2)

关联

100 项与盐酸巴氨西林相关的临床结果

登录后查看更多信息

100 项与盐酸巴氨西林相关的转化医学

登录后查看更多信息

100 项与盐酸巴氨西林相关的专利（医药）

登录后查看更多信息

226

项与盐酸巴氨西林相关的文献（医药）

2016-11-01·International Journal of Infectious Diseases3区 · 医学

Antimicrobial drug use in primary healthcare clinics: a retrospective evaluation

3区 · 医学

ArticleOA

作者: Muhammad Eid Akkawi ; Mohamed Mansor Manan ; Long Chiau Ming ; Shafinaz Shamsuddin ; Syed Tabish Razi Zaidi

OBJECTIVESTo examine the appropriateness of antibiotics prescribed for acute infection based on the Malaysian national antibiotic guidelines and the defined daily dose (DDD) system of the World Health Organization (WHO). This study also aimed to describe the factors influencing the drug use pattern and to investigate the procurement patterns of antibiotics in the primary healthcare setting.METHODSA retrospective cohort follow-up study of randomly selected patients from all patients who received any antibiotic between January and December 2013 was conducted at three primary healthcare clinics in Selangor State of Malaysia. For each patient, the following information was recorded: name of the antibiotic, frequency and dose, and Anatomical Therapeutic Chemical (ATC) group. The defined daily dose per 1000 inhabitants per day was calculated for each antibiotic. The national antibiotic guidelines were used to assess the appropriateness of each antibiotic prescription.RESULTSA total of 735 patients were included in the study. The five most used antibiotics were amoxicillin (1.36g, 35.2%), cloxacillin (0.68g, 26.3%), erythromycin (0.32g, 22.3%), bacampicillin (0.13g, 7.2%), and cephalexin (0.11g, 6.9%). Respiratory tract infections were the most commonly treated infections, and the doctors' preferred antibiotic for the treatment of these infections was amoxicillin. More than 18% of all amoxicillin prescriptions were deemed inappropriate according to the national antibiotic guidelines. In terms of procurement costs, USD 88885 was spent in 2011, USD 219402 in 2012, and USD 233034 in 2013 at the three primary healthcare clinics, an average of USD 180440 per year for the three clinics.CONCLUSIONSThis study reports the antibiotic usage at three primary healthcare clinics in Klang Province. The most prescribed antibiotic was amoxicillin in capsules (250mg), which was mainly prescribed for respiratory infections. Although the national antibiotic guidelines state that amoxicillin is a preferred drug for acute bacterial rhinosinusitis, this drug is also being prescribed for other disease conditions, such as acute pharyngitis and acute tonsillitis. This result shows that current practice is not following the current antibiotic guidelines, which state that phenoxypenicillin should be the preferred drug.

2011-01-01·International Archives of Allergy and Immunology3区 · 医学

Tolerability of Aztreonam in Patients with Cell-Mediated Allergy to β-Lactams

3区 · 医学

Article

作者: Colagiovanni, A. ; Patriarca, G. ; Nucera, E. ; Pecora, V. ; Lombardo, C. ; Aruanno, A. ; De Pasquale, T. ; Rizzi, A. ; Buonomo, A. ; Pascolini, L. ; Sabato, V. ; Schiavino, D.

Background: Cross-reactivity between aztreonam and β-lactams is poor, but tolerability of aztreonam has been assessed in a few groups of patients suffering from IgE-mediated allergy to β-lactams. The aim of this study was to assess the cross-reactivity of aztreonam with other β-lactams and its tolerability in patients with cell-mediated allergy to these drugs. Methods: We studied 78 patients with cell-mediated allergy to β-lactams who underwent skin prick, immediate and delayed-reading intradermal tests as well as patch tests with penicilloyl-polylysine, minor determinant mixture, semi-synthetic penicillins, cephalosporins, aztreonam and imipenem. Patients with negative allergy testing with aztreonam underwent an intramuscular test dosing and were observed for 3 h. Results: Our patients experienced 94 non-immediate reactions; delayed-onset urticaria (34 cases), maculopapular exanthema (13 cases), urticaria/angioedema (15 cases) and itching erythema (13 cases) were the most reported symptoms. Amoxicillin (35 cases), ampicillin (28 cases) and bacampicillin (18 cases) were the most involved drugs. All patients had a positive patch test and/or a positive delayed-reading intradermal test to at least 1 β-lactam antibiotic and none had a positive patch or delayed-reading intradermal test to aztreonam. Then, 65 patients underwent intramuscular test dosing with aztroenam, and none of them had a clinical reaction. Conclusions: Our data confirm the lack of cross-reactivity between β-lactams and aztreonam in patients with cell-mediated allergy to these drugs. Delayed-reading intradermal tests and patch tests with aztreonam represent a simple and rapid diagnostic tool to establish tolerability in β-lactam-allergic patients.

2010-02-18·Journal of Pharmacy and Pharmacology3区 · 医学

Evaluation of the bitterness of antibiotics using a taste sensor

3区 · 医学

Article

作者: Kunitomo, Masaru ; Taniguchi, Akira ; Miyanaga, Yohko ; Kobayashi, Yoshikazu ; Uchida, Takahiro ; Matsuyama, Kenji ; Ikezaki, Hidekazu ; Tanigake, Atsu

AbstractThe bitterness of nine commercial antibiotics (clarithromycin, erythromycin, cefdinil, doxycycline, vancomycin, tetracycline, minocycline, oxytetracycline and bacampicillin) was evaluated in human gustatory sensation tests with nine volunteers. The bitterness of 0.1–0.3 mM solutions (or suspensions in the case of clarithromycin) of the antibiotics was then measured using an artificial multichannel taste sensor. In the sensor measurements, three variables were used to predict estimated bitterness in single and multiple regression analysis and principal component analysis: sensor output as relative value (R), the change of membrane potential caused by adsorption (C) and C/R. Particularly good correlation was obtained between obtained bitterness scores and predicted scores using C from channel 2 of the sensor (r2 = 0.870, P < 0.005) and C/R values for channels 2 and 3 (r2 = 0.947, P < 0.005). The taste sensor was also successful in assessing the bitterness intensity of clarithromycin powder suspensions of various concentrations. Clarithromycin has a low aqueous solubility but is the most bitter of the nine antibiotics. Sensory data from channel 3 of the sensor predicted the bitterness of clarithromycin powder suspensions and their filtered solutions well. Finally, the bitterness intensity of a commercial clarithromycin dry syrup product (Clarith dry syrup, Taisho Pharmaceutical Co. Ltd, Tokyo, Japan) was evaluated in gustatory sensation tests and using the taste sensor. In Clarith dry syrup the drug is coated with aminoalkyl methacrylate polymer using a spray congealing method. The taste sensor results confirmed that the polymer was successful in almost completely masking the bitter taste of the dry syrup product.

100 项与盐酸巴氨西林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00927	盐酸巴氨西林	J01CA06	DB01602

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
急性支气管炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
附件炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
烧伤	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
膀胱炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
睑腺炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
子宫内感染	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
角膜炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
喉炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
淋巴管炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
简单的皮肤和皮肤结构感染(uSSSI)	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
中耳炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
冠周炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
肺炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
脓皮症	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
猩红热	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
继发感染	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
扁桃体炎	日本	Nichi-Iko Pharmaceutical Co., Ltd.	2001-09-12
呼吸道感染	中国	黑龙江福和制药集团股份有限公司	1993-01-01
软组织感染	中国	黑龙江福和制药集团股份有限公司	1993-01-01
泌尿道感染	中国	黑龙江福和制药集团股份有限公司	1993-01-01